Neurogene Inc Dossier
Qualitative Analysis
Business overview
Neurogene Inc. (NASDAQ: NGNE) is a clinical-stage biotechnology company dedicated to developing life-changing genetic medicines for patients and families affected by rare, devastating neurological diseases. The company leverages its proprietary EXACT™ (Expression Attenuation via Construct Tuning) transgene regulation platform, which is designed to deliver therapeutic levels of gene expression within a precise, safe range while mitigating the toxicities commonly associated with conventional gene therapy overexpression. Neurogene's lead clinical program is NGN-401, an investigational adeno-associated virus 9 (AAV9) gene therapy being evaluated as a potential best-in-class, one-time treatment for Rett syndrome. Its second clinical candidate, NGN-101, is a conventional gene therapy in Phase 1/2 development for CLN5 Batten disease.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing NGN-401, an investigational AAV9 gene therapy delivering the full-length human MECP2 gene under the control of the proprietary EXACT transgene regulation technology, through the Embolden registrational trial.
Expected impact: Establish NGN-401 as a potential best-in-class, one-time treatment for Rett syndrome and support a future BLA submission.
Leveraging internal CMC capabilities at the state-of-the-art manufacturing facility in Houston, Texas, to support commercial-grade production and preparing clinical sites for rapid conversion to commercial use.
Expected impact: Ensure future launch readiness and remove the need for comparability studies by keeping commercial scale identical to clinical scale.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Supports pipeline development activities and provides Neurogene with the option to in-license product candidates arising from research conducted in the laboratory of Chief Scientific Officer Dr. Stuart Cobb.
Terms: Neurogene provides funding for collaborative research projects under a Master Collaboration Agreement extended through December 2026.